Design of the Wegener's Granulomatosis Etanercept Trial (WGET). (Q34772654)

4 August 2017

Design of the Wegener's Granulomatosis Etanercept Trial (WGET). (English)

1 reference

4 August 2017

WGET Research Group

1

1 reference

PubMed ID

12161090

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Contemporary Clinical Trials

4 August 2017

1 reference

4 August 2017

23

1 reference

4 August 2017

4

1 reference

4 August 2017

450-468

1 reference

Wegener Granulomatosis: An Analysis of 158 Patients

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Antineutrophil cytoplasmic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Epidemiology of systemic vasculitis: changing incidence or definition?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Longitudinal data analysis for discrete and continuous outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

Covariate adjustment of treatment effects in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900209-X

7 January 2021

10.1016/S0197-2456(02)00209-X

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12161090